Lucira Health (NASDAQ:LHDX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Lucira Health (NASDAQ:LHDX – Get Rating) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $4.00 price objective on the stock. According to Zacks, “Lucira Health Inc. is a medical technology company. It is […]

Related Keywords

California ,United States ,Emeryville ,Canada ,America , ,Morgan Stanley ,Lucira Health ,Zacks Investment Research ,America Corp ,Lucira Health Inc ,Nasdaq ,Lucira Health Get Rating ,Walleye Capital ,Walleye Trading ,Royal Bank ,Get Rating ,Investment Research ,In One Test Kit ,Nasdaq Lhdx ,Lhdx ,Medical ,Upgrade ,